Lapitan Marie Carmela M, Buckley Brian S
Department of Surgery, College of Medicine, Philippine General Hospital, Manila, Philippines.
J Obstet Gynaecol Res. 2011 Aug;37(8):1061-70. doi: 10.1111/j.1447-0756.2010.01486.x. Epub 2011 Apr 12.
Obstructive uropathy is a recognized complication in advanced cervical cancer. Urinary diversion is commonly used to bypass the obstruction and improve renal function. The degree of survival benefit that diversion offers is not well established and its impact on quality of life (QoL) is uncertain. This study considered these factors in order to inform treatment decisions.
This study examined a prospective cohort of patients with advanced cervical cancer and obstructive uropathy in Manila, Philippines. Age, cancer treatment status, comorbidities, serum creatinine level, degree of obstructive uropathy and QoL were recorded at baseline. Patients with creatinine values >150 µmol/L, or who were being considered for radiotherapy or nephrotoxic chemotherapy or manifesting uncontrolled or recurrent uropathy-related urinary tract infection, were offered diversion. Follow-up data collection was at 3, 6, 9 and 12 months from cohort entry.
Of the 230 patients invited, 205 patients joined the cohort. Complete data were available for 198, of whom 93 underwent diversion, 56 required diversion but elected not to receive it, and 49 did not require it. Although survival at 12 months among those who underwent diversion was no greater than among those who required but elected not to receive the procedure, diversion was associated with significantly improved chance of survival in the shorter term. There was no significant difference in the QoL between the groups throughout the study.
With no evidence of an impact on QoL, the decision to offer diversionary surgery might be based solely on a survival benefit, which is modest but potentially important to patients.
梗阻性尿路病是晚期宫颈癌公认的并发症。尿流改道术常用于绕过梗阻并改善肾功能。尿流改道所带来的生存获益程度尚未明确,其对生活质量(QoL)的影响也不确定。本研究考虑了这些因素以指导治疗决策。
本研究对菲律宾马尼拉的晚期宫颈癌合并梗阻性尿路病患者的前瞻性队列进行了研究。在基线时记录年龄、癌症治疗状况、合并症、血清肌酐水平、梗阻性尿路病程度和生活质量。肌酐值>150 µmol/L的患者,或正在考虑接受放疗或肾毒性化疗的患者,或表现为未控制的或复发性尿路病相关尿路感染的患者,接受尿流改道术。随访数据收集在队列入组后的3、6、9和12个月进行。
在邀请的230名患者中,205名患者加入了队列。198名患者有完整数据,其中93名接受了尿流改道术,56名需要尿流改道术但选择不接受,49名不需要。虽然接受尿流改道术的患者12个月时的生存率并不高于需要但选择不接受该手术的患者,但尿流改道在短期内与显著提高的生存机会相关。在整个研究过程中,两组之间的生活质量没有显著差异。
在没有证据表明对生活质量有影响的情况下,提供尿流改道手术的决定可能仅基于生存获益,这一获益虽小但对患者可能很重要。